Impact of SHP2 tyrosine phosphorylation on the development of acquired resistance to allosteric SHP2 inhibitors
Oncotarget · 12.01.2023 · 14 (1) · 281-283
DOI: 10.18632/oncotarget.28392 ↗Kurz gefasst
Editorial in der Zeitschrift Oncotarget, online erschienen am 31.03.2023. Verfasst von Giulia Franciosa und 1 weiteren Autor:innen. Hauptthemen laut MEDLINE: Protein Kinase Inhibitors, Tyrosine. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 8 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
The SH2 domain-containing tyrosine phosphatase 2 (SHP2) is a ubiquitously expressed non-receptor protein tyrosine phosphatase, encoded by the PTPN11 gene. It is positively regulated by upstream receptor tyrosine kinases (RTKs) to activate downstream the RAS-ERK pathway [1].
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Zitieren
APA
Franciosa, G., & Olsen, J. V. (2023). Impact of SHP2 tyrosine phosphorylation on the development of acquired resistance to allosteric SHP2 inhibitors. Oncotarget, 14(1), 281-283. https://doi.org/10.18632/oncotarget.28392
Vancouver
Franciosa G, Olsen JV. Impact of SHP2 tyrosine phosphorylation on the development of acquired resistance to allosteric SHP2 inhibitors. Oncotarget. 2023;14(1):281-283. doi:10.18632/oncotarget.28392
BibTeX
@article{Franciosa2023,
author = {Franciosa, Giulia and Olsen, Jesper V},
title = {Impact of SHP2 tyrosine phosphorylation on the development of acquired resistance to allosteric SHP2 inhibitors},
journal = {Oncotarget},
year = {2023},
volume = {14},
number = {1},
pages = {281--283},
doi = {10.18632/oncotarget.28392}
}
EUVIMED